Lyell Immunopharma Statistics
Total Valuation
LYEL has a market cap or net worth of $492.48 million. The enterprise value is $287.18 million.
Important Dates
The last earnings date was Thursday, March 12, 2026, after market close.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LYEL has 23.31 million shares outstanding. The number of shares has increased by 30.74% in one year.
| Current Share Class | 21.24M |
| Shares Outstanding | 23.31M |
| Shares Change (YoY) | +30.74% |
| Shares Change (QoQ) | +5.62% |
| Owned by Insiders (%) | 1.72% |
| Owned by Institutions (%) | 40.51% |
| Float | 12.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13,680.00 |
| Forward PS | n/a |
| PB Ratio | 1.81 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7,977.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.17.
| Current Ratio | 5.28 |
| Quick Ratio | 5.00 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -86.98% and return on invested capital (ROIC) is -34.44%.
| Return on Equity (ROE) | -86.98% |
| Return on Assets (ROA) | -30.33% |
| Return on Invested Capital (ROIC) | -34.44% |
| Return on Capital Employed (ROCE) | -69.37% |
| Weighted Average Cost of Capital (WACC) | 3.16% |
| Revenue Per Employee | $120 |
| Profits Per Employee | -$914,827 |
| Employee Count | 300 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +80.48% in the last 52 weeks. The beta is -0.15, so LYEL's price volatility has been lower than the market average.
| Beta (5Y) | -0.15 |
| 52-Week Price Change | +80.48% |
| 50-Day Moving Average | 24.14 |
| 200-Day Moving Average | 17.93 |
| Relative Strength Index (RSI) | 39.52 |
| Average Volume (20 Days) | 124,441 |
Short Selling Information
The latest short interest is 815,248, so 3.50% of the outstanding shares have been sold short.
| Short Interest | 815,248 |
| Short Previous Month | 592,027 |
| Short % of Shares Out | 3.50% |
| Short % of Float | 6.61% |
| Short Ratio (days to cover) | 9.61 |
Income Statement
In the last 12 months, LYEL had revenue of $36,000 and -$274.45 million in losses. Loss per share was -$16.06.
| Revenue | 36,000 |
| Gross Profit | 36,000 |
| Operating Income | -201.63M |
| Pretax Income | -274.45M |
| Net Income | -274.45M |
| EBITDA | -190.09M |
| EBIT | -201.63M |
| Loss Per Share | -$16.06 |
Full Income StatementBalance Sheet
The company has $247.22 million in cash and $41.92 million in debt, with a net cash position of $205.30 million or $8.81 per share.
| Cash & Cash Equivalents | 247.22M |
| Total Debt | 41.92M |
| Net Cash | 205.30M |
| Net Cash Per Share | $8.81 |
| Equity (Book Value) | 248.20M |
| Book Value Per Share | 11.68 |
| Working Capital | 211.53M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$150.02 million and capital expenditures -$780,000, giving a free cash flow of -$150.80 million.
| Operating Cash Flow | -150.02M |
| Capital Expenditures | -780,000 |
| Free Cash Flow | -150.80M |
| FCF Per Share | -$6.47 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -560,080.56% |
| Pretax Margin | -762,355.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.74% |
| Shareholder Yield | -30.74% |
| Earnings Yield | -55.73% |
| FCF Yield | -30.62% |
Analyst Forecast
The average price target for LYEL is $27.25, which is 28.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.25 |
| Price Target Difference | 28.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 631.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 2, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jun 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
